Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
Company overview
Disclaimer
Financial review
Conclusions
Appendix
References
This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential,"
"expected," "will," "planned," "pipeline," "outlook," "confident," or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential
product launches, or regarding potential future revenues from any such products; or regarding results of ongoing clinical trials; or regarding ongoing or future share repurchases; or regarding potential future, pending
or announced transactions; regarding potential future sales or earnings; or by discussions of strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D
capabilities and manufacturing; or regarding our approximate estimated peak sales, sales potential and other financial information; or regarding our capital structure; or regarding our focus on material environmental,
social and governance factors; or regarding the consequences of the spin-off of Sandoz and our transformation into a “pure-play" innovative medicines company. Such forward-looking statements are based on the
current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our
expectations could be affected by, among other things: uncertainties regarding the success of key products, commercial priorities and strategy; uncertainties in the research and development of new products,
including clinical trial results and additional analysis of existing clinical data; uncertainties regarding the use of new and disruptive technologies, including artificial intelligence; global trends toward healthcare cost
containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding our ability to realize the
strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; our ability to realize the intended benefits of our separation of Sandoz into a new publicly traded
standalone company; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products;
our performance on environmental, social and governance matters uncertainties in the development or adoption of potentially transformational digital technologies and business models; uncertainties surrounding the
implementation of our new IT projects and systems; uncertainties regarding potential significant breaches of information security or disruptions of our information technology systems; uncertainties regarding actual or
potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this presentation; safety, quality, data integrity, or manufacturing
issues; our performance on and ability to comply with environmental, social and governance measures and requirements; major political, macroeconomic and business developments, including impact of the war in
certain parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a
result of new information, future events or otherwise.
AVROBIO is a registered trademark of AVROBIO, Inc. Voyager Therapeutics is a registered trademark of Voyager Therapeutics, Inc. Bicycle Therapeutics is a registered trademark of Bicycletx Limited. Clovis
Oncology is a registered trademark of Clovis Oncology, Inc. Ionis is a registered trademark of lonis Pharmaceutics, Inc. Legend Biotech is a registered trademark of Nanjing Legend Biotech Co., Ltd. Chong Kun
Dang is a registered trademark of Chong Kun Dang Holdings Corp. Isomorphic Labs is a registered trademark of Isomorphic Labs Limited.
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
2View entire presentation